APO RESEARCH · REPORT
Gene Therapy On Cardiovascular Disease
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Product & engineering
Understand the product.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Selected research
Industry Research
Gene Therapy On Cardiovascular Disease Industry Research Report 2026
Market perspective
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.
Read the full market overview
Report Scope
This report quantifies the global Gene Therapy On Cardiovascular Disease market in terms of revenue (US$ million) and, where applicable, service volume (Kiloton), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Kiloton) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gene Therapy On Cardiovascular Disease.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gene Therapy On Cardiovascular Disease Market by Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Gene Therapy On Cardiovascular Disease Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Gene Therapy On Cardiovascular Disease Segment by Application
Heart Disease
Vascular Disease
Gene Therapy On Cardiovascular Disease Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy On Cardiovascular Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy On Cardiovascular Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy On Cardiovascular Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gene Therapy On Cardiovascular Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Viral Gene Therapy
- Non-Viral Gene Therapy
Applications
- Heart Disease
- Vascular Disease
Companies covered
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Amgen
- Spark Therapeutics
- Akcea Therapeutics
- bluebird bio
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gene Therapy On Cardiovascular Disease by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Viral Gene Therapy
- 2.2.3 Non-Viral Gene Therapy
- 2.3 Gene Therapy On Cardiovascular Disease by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Heart Disease
- 2.3.3 Vascular Disease
- 2.4 Assumptions and Limitations
3 Gene Therapy On Cardiovascular Disease Breakdown Data by Type
- 3.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Type (2021-2026)
- 3.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2027-2032)
4 Gene Therapy On Cardiovascular Disease Breakdown Data by Application
- 4.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Application (2021-2026)
- 4.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2021-2032)
- 5.2 Global Gene Therapy On Cardiovascular Disease Growth Trends by Region
- 5.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gene Therapy On Cardiovascular Disease Historic Market Size by Region (2021-2026)
- 5.2.3 Gene Therapy On Cardiovascular Disease Forecasted Market Size by Region (2027-2032)
- 5.3 Gene Therapy On Cardiovascular Disease Market Dynamics
- 5.3.1 Gene Therapy On Cardiovascular Disease Industry Trends
- 5.3.2 Gene Therapy On Cardiovascular Disease Market Drivers
- 5.3.3 Gene Therapy On Cardiovascular Disease Market Challenges
- 5.3.4 Gene Therapy On Cardiovascular Disease Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue
- 6.1.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue (2021-2026)
- 6.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2021-2026)
- 6.2 Global Gene Therapy On Cardiovascular Disease Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gene Therapy On Cardiovascular Disease Head Office and Area Served
- 6.4 Global Gene Therapy On Cardiovascular Disease Players, Product Type & Application
- 6.5 Global Gene Therapy On Cardiovascular Disease Manufacturers Established Date
- 6.6 Global Gene Therapy On Cardiovascular Disease Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gene Therapy On Cardiovascular Disease Market Size (2021-2032)
- 7.2 North America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 7.4 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gene Therapy On Cardiovascular Disease Market Size (2021-2032)
- 8.2 Europe Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 8.4 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size (2021-2032)
- 9.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gene Therapy On Cardiovascular Disease Market Size (2021-2032)
- 10.2 South America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 10.4 South America Gene Therapy On Cardiovascular Disease Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size (2021-2032)
- 11.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Biogen
- 12.1.1 Biogen Company Information
- 12.1.2 Biogen Business Overview
- 12.1.3 Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.1.4 Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.1.5 Biogen Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.2.4 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Gilead Sciences
- 12.3.1 Gilead Sciences Company Information
- 12.3.2 Gilead Sciences Business Overview
- 12.3.3 Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.3.5 Gilead Sciences Recent Developments
- 12.4 Sarepta Therapeutics
- 12.4.1 Sarepta Therapeutics Company Information
- 12.4.2 Sarepta Therapeutics Business Overview
- 12.4.3 Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.4.5 Sarepta Therapeutics Recent Developments
- 12.5 Alnylam Pharmaceuticals
- 12.5.1 Alnylam Pharmaceuticals Company Information
- 12.5.2 Alnylam Pharmaceuticals Business Overview
- 12.5.3 Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.5.5 Alnylam Pharmaceuticals Recent Developments
- 12.6 Amgen
- 12.6.1 Amgen Company Information
- 12.6.2 Amgen Business Overview
- 12.6.3 Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.6.4 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.6.5 Amgen Recent Developments
- 12.7 Spark Therapeutics
- 12.7.1 Spark Therapeutics Company Information
- 12.7.2 Spark Therapeutics Business Overview
- 12.7.3 Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.7.5 Spark Therapeutics Recent Developments
- 12.8 Akcea Therapeutics
- 12.8.1 Akcea Therapeutics Company Information
- 12.8.2 Akcea Therapeutics Business Overview
- 12.8.3 Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.8.5 Akcea Therapeutics Recent Developments
- 12.9 bluebird bio
- 12.9.1 bluebird bio Company Information
- 12.9.2 bluebird bio Business Overview
- 12.9.3 bluebird bio Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.9.5 bluebird bio Recent Developments
- 12.10 Sunway Biotech
- 12.10.1 Sunway Biotech Company Information
- 12.10.2 Sunway Biotech Business Overview
- 12.10.3 Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.10.5 Sunway Biotech Recent Developments
- 12.11 SIBIONO
- 12.11.1 SIBIONO Company Information
- 12.11.2 SIBIONO Business Overview
- 12.11.3 SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.11.5 SIBIONO Recent Developments
- 12.12 AnGes
- 12.12.1 AnGes Company Information
- 12.12.2 AnGes Business Overview
- 12.12.3 AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.12.4 AnGes Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.12.5 AnGes Recent Developments
- 12.13 Orchard Therapeutics
- 12.13.1 Orchard Therapeutics Company Information
- 12.13.2 Orchard Therapeutics Business Overview
- 12.13.3 Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.13.5 Orchard Therapeutics Recent Developments
- 12.14 Human Stem Cells Institute
- 12.14.1 Human Stem Cells Institute Company Information
- 12.14.2 Human Stem Cells Institute Business Overview
- 12.14.3 Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2021-2026)
- 12.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio
- 12.14.5 Human Stem Cells Institute Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst